Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C10H21N3O.C6H8O7 |
| Molecular Weight | 391.4168 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CC(O)(CC(O)=O)C(O)=O.CCN(CC)C(=O)N1CCN(C)CC1
InChI
InChIKey=PGNKBEARDDELNB-UHFFFAOYSA-N
InChI=1S/C10H21N3O.C6H8O7/c1-4-12(5-2)10(14)13-8-6-11(3)7-9-13;7-3(8)1-6(13,5(11)12)2-4(9)10/h4-9H2,1-3H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
DescriptionCurator's Comment: description was created based on several sources, including http://filobase.bicpu.edu.in/banocide.pdf
Curator's Comment: description was created based on several sources, including http://filobase.bicpu.edu.in/banocide.pdf
Diethylcarbamazine is used in humans, dogs and cats for the treatment of parasitic infections, including pulmonary eosinophilia, loiasis, and lymphatic filariasis. The exact mechanism of its action is unknown, however some studies showed the involvment of inducible nitric-oxide synthase and the cyclooxygenase pathway. Although there is no information on whether the drug is marketed in the USA and Europe, it is currently used in India.
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | BANOCIDE Approved UseUsed for the treatment of individual patients with certain filarial diseases including tropical pulmonary eosinophilia, loiasis, and lymphatic filariasis caused by infection with Wuchereria bancrofti, Brugia malayi, or Brugia timori. |
|||
| Curative | BANOCIDE Approved UseUsed for the treatment of individual patients with certain filarial diseases including tropical pulmonary eosinophilia, loiasis, and lymphatic filariasis caused by infection with Wuchereria bancrofti, Brugia malayi, or Brugia timori. |
|||
| Curative | BANOCIDE Approved UseUsed for the treatment of individual patients with certain filarial diseases including tropical pulmonary eosinophilia, loiasis, and lymphatic filariasis caused by infection with Wuchereria bancrofti, Brugia malayi, or Brugia timori. |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
500 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11865970/ |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIETHYLCARBAMAZINE serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
637 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11865970/ |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIETHYLCARBAMAZINE serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
5840 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11865970/ |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIETHYLCARBAMAZINE serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
7220 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11865970/ |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIETHYLCARBAMAZINE serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
14.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11865970/ |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIETHYLCARBAMAZINE serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
11.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11865970/ |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIETHYLCARBAMAZINE serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
6 mg/kg 1 times / day multiple, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: multiple Dose: 6 mg/kg, 1 times / day Sources: |
unhealthy, 12 to 69 years n = 11 Health Status: unhealthy Condition: filariasis Age Group: 12 to 69 years Sex: M+F Population Size: 11 Sources: |
Other AEs: Fever, Pruritus... Other AEs: Fever (63.6%) Sources: Pruritus (9.1%) Giddiness (9.1%) Joint ache (9.1%) |
2 mg/kg 3 times / day multiple, oral Studied dose Dose: 2 mg/kg, 3 times / day Route: oral Route: multiple Dose: 2 mg/kg, 3 times / day Sources: |
unhealthy, 13 to 46 years n = 11 Health Status: unhealthy Condition: filariasis Age Group: 13 to 46 years Sex: M+F Population Size: 11 Sources: |
Other AEs: Fever, Nausea... Other AEs: Fever Sources: Nausea (27.3%) Vomiting (18.2%) Abdominal discomfort (9.1%) |
50 mg multiple, oral Studied dose |
unhealthy, 37 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 37 years Sex: M Population Size: 10 Sources: |
Other AEs: Lymphadenopathy, Papular urticarial eruption... Other AEs: Lymphadenopathy (100%) Sources: Papular urticarial eruption (30%) Proteinuria (10%) Visual field constriction (20%) Optic nerve pallor (10%) Corneal opacity (90%) Anterior uveitis (10%) Chorioretinitis (10%) |
300 mg multiple, topical Studied dose Dose: 300 mg Route: topical Route: multiple Dose: 300 mg Sources: |
unhealthy, 40 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 40 years Sex: M Population Size: 10 Sources: |
Other AEs: Lymphadenopathy, Papular urticarial eruption... Other AEs: Lymphadenopathy (100%) Sources: Papular urticarial eruption (70%) Proteinuria (30%) Visual field constriction (10%) Optic nerve pallor (20%) Corneal opacity (80%) Anterior uveitis (30%) Chorioretinitis (30%) |
6 mg/kg 1 times / day single, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: single Dose: 6 mg/kg, 1 times / day Co-administed with:: ivermectin(200 ug/kg; single) Sources: albendazole(400 mg; single) |
unhealthy, median age 35 years n = 43 Health Status: unhealthy Condition: Filariasis Age Group: median age 35 years Sex: M+F Population Size: 43 Sources: |
Other AEs: Fatigue, Nausea... Other AEs: Fatigue (grade 2, 5%) Sources: Nausea (grade 2, 2%) Vomiting (grade 2, 2%) Joint pain (grade 2, 2%) Eye swelling (grade 2, 2%) Rash (grade 2, 2%) Dyspnea (grade 2, 2%) |
8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
Other AEs: Fever, Headache... Other AEs: Fever (69%) Sources: Headache (65%) Vertigo (57%) Malaise (49%) Chills (45%) Joint pain (40%) Abdominal pain (37%) Chest pain (33%) Nausea (28%) Neck pain (24%) Vomiting (16%) Muscular pain (14%) Lymph node tenderness (38%) Epididymal tenderness (34%) Nodule (15%) Tinnitus (8%) Convulsion (2%) Eruption (<1%) Shock (<1%) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Fever | 63.6% | 6 mg/kg 1 times / day multiple, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: multiple Dose: 6 mg/kg, 1 times / day Sources: |
unhealthy, 12 to 69 years n = 11 Health Status: unhealthy Condition: filariasis Age Group: 12 to 69 years Sex: M+F Population Size: 11 Sources: |
| Giddiness | 9.1% | 6 mg/kg 1 times / day multiple, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: multiple Dose: 6 mg/kg, 1 times / day Sources: |
unhealthy, 12 to 69 years n = 11 Health Status: unhealthy Condition: filariasis Age Group: 12 to 69 years Sex: M+F Population Size: 11 Sources: |
| Joint ache | 9.1% | 6 mg/kg 1 times / day multiple, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: multiple Dose: 6 mg/kg, 1 times / day Sources: |
unhealthy, 12 to 69 years n = 11 Health Status: unhealthy Condition: filariasis Age Group: 12 to 69 years Sex: M+F Population Size: 11 Sources: |
| Pruritus | 9.1% | 6 mg/kg 1 times / day multiple, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: multiple Dose: 6 mg/kg, 1 times / day Sources: |
unhealthy, 12 to 69 years n = 11 Health Status: unhealthy Condition: filariasis Age Group: 12 to 69 years Sex: M+F Population Size: 11 Sources: |
| Fever | 2 mg/kg 3 times / day multiple, oral Studied dose Dose: 2 mg/kg, 3 times / day Route: oral Route: multiple Dose: 2 mg/kg, 3 times / day Sources: |
unhealthy, 13 to 46 years n = 11 Health Status: unhealthy Condition: filariasis Age Group: 13 to 46 years Sex: M+F Population Size: 11 Sources: |
|
| Vomiting | 18.2% | 2 mg/kg 3 times / day multiple, oral Studied dose Dose: 2 mg/kg, 3 times / day Route: oral Route: multiple Dose: 2 mg/kg, 3 times / day Sources: |
unhealthy, 13 to 46 years n = 11 Health Status: unhealthy Condition: filariasis Age Group: 13 to 46 years Sex: M+F Population Size: 11 Sources: |
| Nausea | 27.3% | 2 mg/kg 3 times / day multiple, oral Studied dose Dose: 2 mg/kg, 3 times / day Route: oral Route: multiple Dose: 2 mg/kg, 3 times / day Sources: |
unhealthy, 13 to 46 years n = 11 Health Status: unhealthy Condition: filariasis Age Group: 13 to 46 years Sex: M+F Population Size: 11 Sources: |
| Abdominal discomfort | 9.1% | 2 mg/kg 3 times / day multiple, oral Studied dose Dose: 2 mg/kg, 3 times / day Route: oral Route: multiple Dose: 2 mg/kg, 3 times / day Sources: |
unhealthy, 13 to 46 years n = 11 Health Status: unhealthy Condition: filariasis Age Group: 13 to 46 years Sex: M+F Population Size: 11 Sources: |
| Anterior uveitis | 10% | 50 mg multiple, oral Studied dose |
unhealthy, 37 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 37 years Sex: M Population Size: 10 Sources: |
| Chorioretinitis | 10% | 50 mg multiple, oral Studied dose |
unhealthy, 37 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 37 years Sex: M Population Size: 10 Sources: |
| Optic nerve pallor | 10% | 50 mg multiple, oral Studied dose |
unhealthy, 37 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 37 years Sex: M Population Size: 10 Sources: |
| Proteinuria | 10% | 50 mg multiple, oral Studied dose |
unhealthy, 37 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 37 years Sex: M Population Size: 10 Sources: |
| Lymphadenopathy | 100% | 50 mg multiple, oral Studied dose |
unhealthy, 37 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 37 years Sex: M Population Size: 10 Sources: |
| Visual field constriction | 20% | 50 mg multiple, oral Studied dose |
unhealthy, 37 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 37 years Sex: M Population Size: 10 Sources: |
| Papular urticarial eruption | 30% | 50 mg multiple, oral Studied dose |
unhealthy, 37 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 37 years Sex: M Population Size: 10 Sources: |
| Corneal opacity | 90% | 50 mg multiple, oral Studied dose |
unhealthy, 37 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 37 years Sex: M Population Size: 10 Sources: |
| Visual field constriction | 10% | 300 mg multiple, topical Studied dose Dose: 300 mg Route: topical Route: multiple Dose: 300 mg Sources: |
unhealthy, 40 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 40 years Sex: M Population Size: 10 Sources: |
| Lymphadenopathy | 100% | 300 mg multiple, topical Studied dose Dose: 300 mg Route: topical Route: multiple Dose: 300 mg Sources: |
unhealthy, 40 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 40 years Sex: M Population Size: 10 Sources: |
| Optic nerve pallor | 20% | 300 mg multiple, topical Studied dose Dose: 300 mg Route: topical Route: multiple Dose: 300 mg Sources: |
unhealthy, 40 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 40 years Sex: M Population Size: 10 Sources: |
| Anterior uveitis | 30% | 300 mg multiple, topical Studied dose Dose: 300 mg Route: topical Route: multiple Dose: 300 mg Sources: |
unhealthy, 40 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 40 years Sex: M Population Size: 10 Sources: |
| Chorioretinitis | 30% | 300 mg multiple, topical Studied dose Dose: 300 mg Route: topical Route: multiple Dose: 300 mg Sources: |
unhealthy, 40 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 40 years Sex: M Population Size: 10 Sources: |
| Proteinuria | 30% | 300 mg multiple, topical Studied dose Dose: 300 mg Route: topical Route: multiple Dose: 300 mg Sources: |
unhealthy, 40 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 40 years Sex: M Population Size: 10 Sources: |
| Papular urticarial eruption | 70% | 300 mg multiple, topical Studied dose Dose: 300 mg Route: topical Route: multiple Dose: 300 mg Sources: |
unhealthy, 40 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 40 years Sex: M Population Size: 10 Sources: |
| Corneal opacity | 80% | 300 mg multiple, topical Studied dose Dose: 300 mg Route: topical Route: multiple Dose: 300 mg Sources: |
unhealthy, 40 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 40 years Sex: M Population Size: 10 Sources: |
| Dyspnea | grade 2, 2% | 6 mg/kg 1 times / day single, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: single Dose: 6 mg/kg, 1 times / day Co-administed with:: ivermectin(200 ug/kg; single) Sources: albendazole(400 mg; single) |
unhealthy, median age 35 years n = 43 Health Status: unhealthy Condition: Filariasis Age Group: median age 35 years Sex: M+F Population Size: 43 Sources: |
| Eye swelling | grade 2, 2% | 6 mg/kg 1 times / day single, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: single Dose: 6 mg/kg, 1 times / day Co-administed with:: ivermectin(200 ug/kg; single) Sources: albendazole(400 mg; single) |
unhealthy, median age 35 years n = 43 Health Status: unhealthy Condition: Filariasis Age Group: median age 35 years Sex: M+F Population Size: 43 Sources: |
| Joint pain | grade 2, 2% | 6 mg/kg 1 times / day single, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: single Dose: 6 mg/kg, 1 times / day Co-administed with:: ivermectin(200 ug/kg; single) Sources: albendazole(400 mg; single) |
unhealthy, median age 35 years n = 43 Health Status: unhealthy Condition: Filariasis Age Group: median age 35 years Sex: M+F Population Size: 43 Sources: |
| Nausea | grade 2, 2% | 6 mg/kg 1 times / day single, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: single Dose: 6 mg/kg, 1 times / day Co-administed with:: ivermectin(200 ug/kg; single) Sources: albendazole(400 mg; single) |
unhealthy, median age 35 years n = 43 Health Status: unhealthy Condition: Filariasis Age Group: median age 35 years Sex: M+F Population Size: 43 Sources: |
| Rash | grade 2, 2% | 6 mg/kg 1 times / day single, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: single Dose: 6 mg/kg, 1 times / day Co-administed with:: ivermectin(200 ug/kg; single) Sources: albendazole(400 mg; single) |
unhealthy, median age 35 years n = 43 Health Status: unhealthy Condition: Filariasis Age Group: median age 35 years Sex: M+F Population Size: 43 Sources: |
| Vomiting | grade 2, 2% | 6 mg/kg 1 times / day single, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: single Dose: 6 mg/kg, 1 times / day Co-administed with:: ivermectin(200 ug/kg; single) Sources: albendazole(400 mg; single) |
unhealthy, median age 35 years n = 43 Health Status: unhealthy Condition: Filariasis Age Group: median age 35 years Sex: M+F Population Size: 43 Sources: |
| Fatigue | grade 2, 5% | 6 mg/kg 1 times / day single, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: single Dose: 6 mg/kg, 1 times / day Co-administed with:: ivermectin(200 ug/kg; single) Sources: albendazole(400 mg; single) |
unhealthy, median age 35 years n = 43 Health Status: unhealthy Condition: Filariasis Age Group: median age 35 years Sex: M+F Population Size: 43 Sources: |
| Muscular pain | 14% | 8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
| Nodule | 15% | 8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
| Vomiting | 16% | 8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
| Convulsion | 2% | 8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
| Neck pain | 24% | 8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
| Nausea | 28% | 8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
| Chest pain | 33% | 8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
| Epididymal tenderness | 34% | 8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
| Abdominal pain | 37% | 8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
| Lymph node tenderness | 38% | 8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
| Joint pain | 40% | 8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
| Chills | 45% | 8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
| Malaise | 49% | 8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
| Vertigo | 57% | 8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
| Headache | 65% | 8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
| Fever | 69% | 8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
| Tinnitus | 8% | 8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
| Eruption | <1% | 8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
| Shock | <1% | 8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no [Activation >10 uM] | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| yes [Inhibition 10 uM] | ||||
| yes [Inhibition 10 uM] | ||||
| yes |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| likely | ||||
| likely | ||||
| no | no (co-administration study) Comment: Coadministration of refampicin/ketoconazole did not affect the exposure of diethylcarbamazine. |
|||
| no | no (co-administration study) Comment: Coadministration of refampicin/ketoconazole did not affect the exposure of diethylcarbamazine. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Antituberculosis activity of certain antifungal and antihelmintic drugs. | 1999 |
|
| Compliance with the mass chemotherapy program for lymphatic filariasis. | 2001 Dec |
|
| A community-based trial for the control of lymphatic filariasis and iodine deficiency using salt fortified with diethylcarbamazine and iodine. | 2001 Dec |
|
| Severe reactions to filarial chemotherapy and release of Wolbachia endosymbionts into blood. | 2001 Dec 1 |
|
| Possible role of nitric oxide and arachidonic acid pathways in hypoxia-induced contraction of rabbit coronary artery rings. | 2001 Feb |
|
| Effect of drugs used for neuropathic pain management on tetrodotoxin-resistant Na(+) currents in rat sensory neurons. | 2001 Jan |
|
| Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. | 2001 Jan |
|
| Filariasis control: ethics, economics, and good science. | 2001 Jul 21 |
|
| Annual single-dose diethylcarbamazine plus ivermectin for control of bancroftian filariasis: comparative efficacy with and without vector control. | 2001 Jun |
|
| Bancroftian filariasis in residents of Oman. | 2001 Jun 22 |
|
| Tropical pulmonary eosinophilia and filariasis in Pakistan. | 2001 Mar |
|
| The impact of 34 years of massive DEC chemotherapy on Wuchereria bancrofti infection and transmission: the Maupiti cohort. | 2001 Mar |
|
| Intraoral filarial infestation: an atypical presentation. | 2001 Nov |
|
| Lymphatic filariasis in children: adenopathy and its evolution in two young girls. | 2001 Sep |
|
| Efficacy of DEC against Ascaris and hookworm infections in schoolchildren. | 2001 Sep |
|
| A randomized, double-blind, placebo-controlled study with diethylcarbamazine for the treatment of hydrocoele in an area of Tanzania endemic for lymphatic filariasis. | 2001 Sep-Oct |
|
| Subconjunctival Loa Loa worm: case report. | 2002 |
|
| Genetic variability of the human filarial parasite, Wuchereria bancrofti in South India. | 2002 Apr |
|
| The impact of single-dose diethylcarbamazine treatment of bancroftian filariasis in a low-endemicity setting in Egypt. | 2002 Aug |
|
| Progress towards, and challenges for, the elimination of filariasis from Pacific-island communities. | 2002 Dec |
|
| Major progress toward eliminating lymphatic filariasis. | 2002 Dec 5 |
|
| Mass treatment to eliminate filariasis in Papua New Guinea. | 2002 Dec 5 |
|
| Prevalence and intensity of Wuchereria bancrofti antigenaemia in Sri Lanka by Og4C3 ELISA using filter paper-absorbed whole blood. | 2002 Jan-Feb |
|
| [Recommendations for the treatment of bancroftian filariasis in symptomless and diseased patients]. | 2002 Jan-Feb |
|
| New goals set for filariasis elimination in India. | 2002 Jul |
|
| Efficacy of co-administration of albendazole and diethylcarbamazine against geohelminthiases: a study from South India. | 2002 Jun |
|
| Microfilaria in thyroid aspirate. | 2002 Mar |
|
| Bacterial endosymbionts of Onchocerca volvulus in the pathogenesis of posttreatment reactions. | 2002 Mar 15 |
|
| Case 1-2002: Loa loa. | 2002 May 30 |
|
| Electron microscopic and molecular identification of Wolbachia endosymbionts from Onchocerca lupi: implications for therapy. | 2002 May 30 |
|
| Neoplastic change in Onchocerca volvulus and its relation to ivermectin treatment. | 2002 Nov |
|
| Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. | 2002 Nov |
|
| Prevalence of diurnally subperiodic bancroftian filariasis among the Nicobarese in Andaman and Nicobar Islands, India: effect of age and gender. | 2002 Nov |
|
| Case report: intraocular localization of Mansonella perstans in a patient from south Chad. | 2002 Nov-Dec |
|
| Red blood cell antioxidant levels in Wuchereria bancrofti infection. | 2002 Oct |
|
| Treatment of Brugia timori and Wuchereria bancrofti infections in Indonesia using DEC or a combination of DEC and albendazole: adverse reactions and short-term effects on microfilariae. | 2002 Oct |
|
| The pharmacokinetics, safety and tolerability of the co-administration of diethylcarbamazine and albendazole. | 2002 Sep |
|
| The influence of the mass administration of diethylcarbamazine, alone or with albendazole, on the prevalence of filarial antigenaemia. | 2002 Sep |
|
| Targeting apoptotic signalling pathway and pro-inflammatory cytokine expression as therapeutic intervention in TPE induced lung damage. | 2003 |
|
| A comparison of the efficacy of single doses of albendazole, ivermectin, and diethylcarbamazine alone or in combinations against Ascaris and Trichuris spp. | 2003 |
|
| Long-term population migration: an important aspect to be considered during mass drug administration for elimination of lymphatic filariasis. | 2003 Apr |
|
| Long-term follow-up of treatment with diethylcarbamazine on anti-filarial IgG4: dosage, compliance, and differential patterns in adults and children. | 2003 Jan |
|
| Setaria cervi: in vitro released collagenases and their inhibition by Wuchereria bancrofti infected sera. | 2003 Mar |
|
| Ensuring supplies of quality diethylcarbamazine citrate (DEC). | 2003 May |
Sample Use Guides
Lymphatic filariasis: 6 mg/kg daily for 12 days administered orally, preferably in divided doses after meals (W. bancrofti infection); 3-6 mg/kg daily for 6-12 days administered orally, preferably in divided doses after meals (B. malayi and B. timori infections). Tropical pulmonary eosinophilia: a dose of 8 mg/kg daily for 14 days repeated, as necessary, if symptoms return.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CFR |
21 CFR 520.622B
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
||
|
NCI_THESAURUS |
C250
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
||
|
CFR |
21 CFR 520.622
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
||
|
CFR |
21 CFR 520.622A
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
||
|
CFR |
21 CFR 520.622C
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID4045555
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
PRIMARY | |||
|
DBSALT000975
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
PRIMARY | |||
|
80513
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
PRIMARY | |||
|
OS1Z389K8S
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
PRIMARY | |||
|
C65379
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
PRIMARY | |||
|
216-696-6
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
PRIMARY | |||
|
1193006
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
PRIMARY | |||
|
m4398
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL684
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
PRIMARY | |||
|
1642-54-2
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
PRIMARY | |||
|
DIETHYLCARBAMAZINE DIHYDROGEN CITRATE
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
PRIMARY | Description: A white, crystalline powder; odourless or almost odourless.Solubility: Very soluble in water; soluble in 35 parts of ethanol (~750 g/l) TS; practically insoluble in ether R.Category: Filaricide.Storage: Diethylcarbamazine dihydrogen citrate should be kept in a tightly closed container, protected from light.Additional information: Diethylcarbamazine dihydrogen citrate is hygroscopic; it has an acid and bitter taste. Even in the absenceof light, Diethylcarbamazine dihydrogen citrate is gradually degraded on exposure to a humid atmosphere, the decompositionbeing faster at higher temperatures.Definition: Diethylcarbamazine dihydrogen citrate contains not less than 98.0% and not more than 101.0% of C10H21N3O,C6H8O7, calculated with reference to the anhydrous substance. | ||
|
SUB01686MIG
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
PRIMARY | |||
|
203175
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
PRIMARY | RxNorm | ||
|
OS1Z389K8S
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
PRIMARY | |||
|
100000087926
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
PRIMARY | |||
|
6421
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
PRIMARY | |||
|
15432
Created by
admin on Fri Dec 15 15:05:23 GMT 2023 , Edited by admin on Fri Dec 15 15:05:23 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
